Granzyme A Mouse anti-Human, Unlabeled, Clone: CB9, BD

Description

• The primary mechanism by which cytotoxic T cells eliminate virally infected cells is by granule exocytosis
• The release of cytotoxic granule contents by cytotoxic T lymphocytes (CTL) triggers apoptotic target cell death
• CTL granules contain a pore-forming protein, perforin, and a group of serine proteases called granzymes
• In the classic model, perforins create holes in the target cell membrane, allowing entrance of the granzymes
• Granzyme A and B are the predominant granzymes activated after CTL activation, but each act via an independent apoptotic pathway; granzyme B is activated immediately, while granzyme A acts hours later
• Granzyme B has been shown to induce apoptosis and to cleave a number of substrates which are similar in specificity to those of the caspase family of proteinases
• Granzyme B can cleave substrates, such as DNA-PKcs, and nuclear mitotic apparatus protein (NuMA)
• Furthermore, Granzyme B can also cleave substrates such as Bid and DFF45 in a caspase-independent fashion
• Studies involving mice which are deficient in both granzyme A and B suggest a model whereby the granzyme B pathway may have evolved as the major apoptotic pathway with the granzyme A pathway acting as a backup
• However, further research is needed to delineate the components of these distinct pathways
• Clone CB9 recognizes human granzyme A
• Purified human granzyme A was used as the immunogen
• This antibody is routinely tested by flow cytometric analysis
• Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature
• Host Species: Mouse Clone: CB9 Isotype: IgG1 Cross Reactivity: Human Flow Cytometry, Immunoprecipitation, Intracellular Staining